TTP’s market-wide review of ophthalmic drug delivery highlights a critical disconnect between the therapies emerging in the pipeline and the technologies available to deliver them. As biologics and gene therapies increasingly target high-prevalence retinal diseases, current delivery methods: intravitreal, suprachoroidal, and subretinal, face fundamental anatomical and practical limitations.
While effective in specific contexts, these approaches struggle to scale to the volumes required for widespread treatment. The result is a growing risk that delivery, not therapy, becomes the limiting factor.
Addressing this will require a step-change in how the retina is accessed, moving towards solutions that are less invasive, lower in procedural complexity, and viable beyond the operating theatre. TTP is exploring novel device concepts and enabling technologies designed around these requirements, with a focus on what true scalability demands.
